TISIDB

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Peripheral membrane protein Cytoplasmic side Cell projection, growth cone membrane Peripheral membrane protein Cytoplasmic side Cell junction, synapse Cell projection, filopodium membrane Peripheral membrane protein Note=Cytoplasmic surface of growth cone and synaptic plasma membranes.
Domain	PF00612 IQ calmodulin-binding motif PF06614 Neuromodulin PF10580 Gap junction protein N-terminal region
Function	This protein is associated with nerve growth. It is a major component of the motile "growth cones" that form the tips of elongating axons. Plays a role in axonal and dendritic filopodia induction.

> Gene Ontology [ TOP ]
Biological Process	GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway GO:0007409 axonogenesis GO:0007411 axon guidance GO:0008037 cell recognition GO:0008038 neuron recognition GO:0010001 glial cell differentiation GO:0016198 axon choice point recognition GO:0030031 cell projection assembly GO:0031099 regeneration GO:0042063 gliogenesis GO:0042246 tissue regeneration GO:0045165 cell fate commitment GO:0046847 filopodium assembly GO:0048667 cell morphogenesis involved in neuron differentiation GO:0051489 regulation of filopodium assembly GO:0060491 regulation of cell projection assembly GO:0061564 axon development GO:0097485 neuron projection guidance
Molecular Function	GO:0001786 phosphatidylserine binding GO:0005516 calmodulin binding GO:0005543 phospholipid binding GO:0035091 phosphatidylinositol binding GO:0035727 lysophosphatidic acid binding GO:0072341 modified amino acid binding GO:1901981 phosphatidylinositol phosphate binding
Cellular Component	GO:0014069 postsynaptic density GO:0030175 filopodium GO:0030424 axon GO:0030426 growth cone GO:0030427 site of polarized growth GO:0031253 cell projection membrane GO:0031527 filopodium membrane GO:0032584 growth cone membrane GO:0060076 excitatory synapse GO:0098794 postsynapse GO:0098858 actin-based cell projection GO:0099572 postsynaptic specialization

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-373760: L1CAM interactions

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between GAP43 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of GAP43 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of GAP43 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.368	0.631
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-2.02	0.0902
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.828	0.432
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.004	0.994
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.318	0.773
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.41	0.754
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.045	0.955
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.607	0.574
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.112	0.386
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.589	0.264
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.828	0.237
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.651	0.0434

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of GAP43 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GAP43. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GAP43. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GAP43. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GAP43. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of GAP43 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between GAP43 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	GAP43
Name	growth associated protein 43
Aliases	B-50; PP46; neuron growth-associated protein 43; neuromodulin; nerve growth-related peptide GAP43; axonal me ......
Chromosomal Location	3q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting GAP43 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse GAP43